New treatment options for myelodysplastic syndrome and acute myeloid leukemia
A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
This study is exploring new treatment options for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by looking at their genetic makeup and developing targeted therapies that could help improve their health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Avantgen, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10920336 on NIH RePORTER |
What this research studies
This research investigates innovative treatment strategies for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It aims to develop targeted therapies that could improve outcomes for patients who currently have limited treatment options. The approach focuses on understanding the genetic mutations associated with these conditions and utilizing advanced biomanufacturing techniques to create effective therapies. Patients may be involved in clinical trials to evaluate the safety and efficacy of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia, particularly those who have not responded well to existing therapies.
Not a fit: Patients with early-stage MDS who are asymptomatic and do not require treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide more effective treatment options and improve survival rates for patients with MDS and AML.
How similar studies have performed: Other research has shown promise in developing targeted therapies for AML, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
San Diego, United States
- Avantgen, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Fan, Xiaomin — Avantgen, INC.
- Study coordinator: Fan, Xiaomin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.